Home › NDC Lookup › RxCUI directory › RxCUI 1366550

24 HR budesonide 9 MG Extended Release Oral Tablet — RxCUI 1366550

RxNorm drug concept · Semantic clinical drug
RxCUI 1366550 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1366550
Official name24 HR budesonide 9 MG Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asbudesonide 9 MG 24HR Extended Release Oral Tablet
FDA products mapped4
Package NDCs mapped6
Reported Medicaid activity (SDUD)3,246 prescriptions · 30 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Budesonide Nasal Spray: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • You might notice some improvement on the very first day, but don't give up if you don't feel a big difference right away. The full benefit from this spray usually builds up over ab...
  • How long does it take for budesonide nasal spray to actually work?
  • Children 6 and older can use budesonide nasal spray, but an adult should supervise use for kids ages 6 to under 12. The spray should not be used in children under 6. One thing to k...
  • Can my child use this spray, and is it safe for long-term use in kids?
📖 Read our full Budesonide Nasal Spray guide →

🕸️ Concept Web — How 24 HR budesonide 9 MG Extended Release Oral Tabl... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR budesonide 9 MG Extended Release Oral Tablet RxCUI 1366550

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Budesonide 19831
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Uceris 1366551
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Budesonide Extended Release Oral Tablet 1366549
    • Budesonide Oral Product 1151338
    • Budesonide Pill 1151339
    • Budesonide Extended Release Oral Tablet [Uceris] 1366553
    • Uceris Oral Product 1366554
    • Uceris Pill 1366555
    • Extended Release Oral Tablet 316945
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Budesonide 9 MG SCDC · 1366548
  • Budesonide Extended Release Oral Tablet SCDF · 1366549
  • Budesonide Oral Product SCDG · 1151338
  • Budesonide Pill SCDG · 1151339

Brand-Name Concepts

📦 FDA Products & Package NDCs

4 products · 6 package NDCs
6 package NDCs map to RxCUI 1366550 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00378-4500-93 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTI... Budesonide Mylan Pharmaceuticals Inc. 2020-10-21
00591-2510-30 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0591-2... Budesonide Actavis Pharma, Inc. 2018-07-05
68012-0309-01 2 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (68012-309-01) Uceris Santarus Inc. 2013-01-14
68012-0309-02 2 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (68012-309-02) Uceris Santarus Inc. 2013-01-14
68012-0309-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (68012-309-30) Uceris Santarus Inc. 2013-01-14
68682-0309-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (68682-309-30) budesonide Oceanside Pharmaceuticals 2018-07-10
Observed labelers: Santarus Inc. (3) · Actavis Pharma, Inc. (1) · Mylan Pharmaceuticals Inc. (1) · Oceanside Pharmaceuticals (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.